The effects and side effects of tucatinib

Tucatinib (tucatinib) is mainly used to treat HER2-positive metastatic breast cancer. Clinical trials have shown that triple therapy with tucatinib, trastuzumab, and capecitabine can effectively prolong progression-free survival (PFS) compared with trastuzumab and capecitabine alone. In patients with HER2-positive metastatic breast cancer, this triple therapy significantly prolonged PFS compared with trastuzumab and capecitabine alone.

Tucatinib can significantly improve the prognosis of patients with HER2-positive metastatic breast cancer compared with triple therapy It was shown to have significant advantages in extending progression-free survival (PFS). Tucatinib has also shown efficacy in controlling brain metastasis as it is able to cross the blood-brain barrier and inhibit brain metastasis of HER2-positive breast cancer.

However, tucatinib may also cause some side effects, such as nausea, vomiting, diarrhea, fatigue, rash, etc. Physicians evaluate the benefits and risks on a patient-specific basis and monitor patients for treatment responses and adverse effects.

It is understood that the original drug Tucatinib has not yet been launched in China, so it has not entered the scope of domestic medical insurance. Patients in need cannot yet purchase this drug in pharmacies or hospitals. The price of the European version of tucatinib original drug sold overseas is around RMB 72,000 (the price may fluctuate due to exchange rates), which is expensive. There are also generic drugs of tucatinib produced in other countries. The price of Tucatinib produced by a Lao pharmaceutical factory is around 6,400 yuan (the price may fluctuate due to the exchange rate). The price is much cheaper than the original drug, and the ingredients of foreign generic drugs are basically the same as the original drug.